Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase In Years
Summary
Eli Lilly announced its acquisition of Kelonia Therapeutics, a gene therapy developer focused on cancer treatment, in a deal valued at up to \$7 billion, marking the largest acquisition of a venture-backed biotech company in years. Kelonia's platform, which launched from stealth just four years ago, utilizes an in vivo gene placement system to reprogram patients' T-cells inside the body, offering a rapid, simpler "off-the-shelf format" for CAR T-cell therapies. This approach has shown promising clinical trial results, particularly for multiple myeloma. The agreement includes \$3.25 billion upfront and up to \$3.75 billion in milestone payments. This acquisition underscores a growing trend of significant investments in in vivo therapeutics, as evidenced by Lilly's prior purchase of Orna Therapeutics and other major deals like AbbVie's acquisition of Capstan Therapeutics.
Key takeaway
Eli Lilly is acquiring Kelonia Therapeutics for up to \$7 billion, marking the largest venture-backed biotech purchase in years, to advance its in vivo CAR T-cell therapy pipeline. Kelonia's platform enables rapid, off-the-shelf T-cell reprogramming inside the body to attack cancer, with promising early results in multiple myeloma. This deal highlights the growing strategic value of in vivo gene therapies for simpler, more accessible cancer treatments.
Topics
- Eli Lilly
- Kelonia Therapeutics
- Gene Therapy
- CAR T-cell Therapy
- In Vivo Therapeutics
Best for: Executive, Investor, Entrepreneur
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by Artificial intelligence - Crunchbase News.